Metabolon
operates its HD4 untargeted metabolomics platform alongside targeted panels (lipidomics, gut metabolites, oxidative stress), backed by a proprietary reference library, serving both discovery-stage biomarker research and pharmacometabolomic studies of drug response for pharma clients.
- Country
- United States
untargeted
us
Coverage
| CN | EU | US | |
|---|---|---|---|
| bioinformatics-omics | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Metabolomics (service) | bioinformatics-omics | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.